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Background: Kaiso protein has been identified as a new member of the POZ-ZF subfamily of transcription factors
that are involved in development and cancer. There is consistent evidence of the role of Kaiso and its involvement
in human tumorigenesis but there is no evidence about its role in hematopoietic differentiation or establishment of
chronic myeloid leukemia (CML). We used, normal K562 cell line, established from a CML patient in blast crisis, and
imatinib-resistant K562 cell line, to investigate the specific distribution of Kaiso and their contribution to the cell
differentiation status of the blast crisis of CML (CML-BP).
Results: We found cytoplasmic expression of Kaiso, in K562 cells and patients, confirmed by immunofluorescence,
immunohistochemistry and western blot of cytoplasmic protein fraction. Kaiso was weakly expressed in the
imatinib-resistant K562 cell line confirmed by immunofluorescence and western blot. The cytoplasmic expression of
Kaiso was not modified when the K562 cells were treated for 16 h with imatinib 0.1 and 1 μM. In our study, small
interfering RNA (siRNA) was introduced to down regulate the expression of Kaiso and p120ctn in K562 cell line.
Kaiso and p120ctn were down regulated individually (siRNA-Kaiso or siRNA-p120ctn) or in combination using a
simultaneous co-transfection (siRNA-Kaiso/p120ctn). We next investigated whether knockdown either Kaiso or
p120ctn alone or in combination affects the cell differentiation status in K562 cells. After down regulation we
analyzed the expression of hematopoietic cell differentiation and proliferation genes: SCF, PU-1, c-MyB, C/EBPα,
Gata-2 and maturation markers of hematopoietic cells expressed in the plasma membrane: CD15, CD11b, CD33,
CD117. The levels of SCF and c-MyB were increased by 1000% and 65% respectively and PU-1, Gata-2 and C/EBPα
were decreased by 66%, 50% and 80% respectively, when Kaiso levels were down regulated by siRNA. The results
were similar when both Kaiso and p120ctn were down regulated by siRNA. The increased expression of SCF and
decreased expression of GATA-2 could be responsible by the higher cell viability detected in K562 cells double
knock-down of both Kaiso and p120ctn. Finally, we studied the effect of knock-down either Kaiso or p120ctn, alone
or in combination on CD15, CD11b, CD33 and Cd117 expression. Using siRNA approach a reduction of 35%, 8%
and 13% in CD15, CD33 and CD117 levels respectively, were achieved in all transfections, when compared to
scrambled knock-down cells.
Conclusion: These results suggest that both Kaiso and p120ctn, contributes to maintaining the differentiated state
of the K562 cells and similar to other cancers, cytoplasmic localization of Kaiso is related to a poor prognosis in
CML-BP. By the broad and profound effects on the expression of genes and markers of hematopoietic
differentiation produced by Kaiso knock-down, these findings reveal Kaiso as a potential target for selective therapy
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Chronic myeloid leukemia (CML) is a clonal disorder of
the pluripotent hematopoietic stem cell (resulting in a pro-
gressive granulocytosis), in which a reciprocal translocation
t(9;22)(q34;q11) forms a Philadelphia (Ph) chromosome
and creates a novel fusion gene, bcrabl [1]. Its correspond-
ing protein has a constitutively activated tyrosine kinase
that is central to the pathogenesis of CML [2].
The disease follows a triphasic course: an initial chronic
phase (CP) lasting 3–5 years, an accelerated phase (AP)
lasting 6–18 months and the final phase called blast crisis
(BC) or acute leukemia, defined hematologically by the in-
crease of leukemic blasts (myeloid or lymphoid) in periph-
eral blood and/or bone marrow (more than 20%). At this
stage of the disease, many patients died between three and
six months, because they are refractory to most treat-
ments, including resistance to imatinib [3].
Imatinib has emerged as the leading compound to treat
CML. It targets the ATP-binding site of different tyrosine
kinases including bcr-abl, the platelet-derived growth factor
receptor [4], and C-KIT [5]. Imatinib selectively induces
growth arrest and apoptosis of bcr-abl-positive leukemia
cells with minimal effect on normal hematopoietic progeni-
tors [6-8]. Of note, this agent has proven very effective in
patients in chronic phase of CML [9] and to a lesser extent,
in patients in accelerated phase and blast crisis [7].
Although treatment with imatinib achieves complete
hematologic remission in the great majority of patients with
CML, total cytogenetic and molecular responses are rela-
tively rare events [10].
It has become widely accepted that activation of the
bcr-abl tyrosine kinase is causative for CML [11]. Still,
involvement of additional molecular events in the patho-
genesis of CML has been demonstrated [12]. For in-
stance, in BC of CML elevated levels of β-catenin lead to
expansion of the granulocyte-macrophage progenitor
(GMP) subset [12], and inactivation of the transcription
factor JunB is able to increase the number of long-term
hematopoietic stem cells (LT-HSC) and GMP in a mur-
ine model of myeloproliferative disease [13].
Several recent studies about the participation of Kaiso
in the β-catenin regulation have been obtained, when it
has been found that Kaiso inhibits activation mediated
by β-catenin of the Mmp7 gene (also known as matrily-
sin), which is well known for metastatic spread [14].
Another study suggests that Kaiso can regulate TCF/
LEF1-activity, via modulating HDAC1 and β-catenin-
complex formation [15]. This shows that Kaiso can
directly regulate the signaling pathway of canonical
Wnt/β-catenin widely known for its involvement in
human tumors. Other evidence also showed that Kaiso
rescues the dorsalization of the mesoderm produced by
β-catenin and siamois in Xenopus laevis [16]. Siamois is
a high mobility group (HMG)-box transcription factorthat promotes the dorsalization of the mesoderm of
amphibians and is a well-known target of the canonical
Wnt pathway involving TCF/LEF. The Kaiso overexpres-
sion decreases the ability of TCF/LEF to interact with
β-catenin, which implies that Kaiso and TCF/LEF are
associated in the nucleus [17]. Despite this evidence the
role of Kaiso in hematopoiesis has not been explored.
Who is Kaiso? Kaiso protein (encoded by the zinc finger
and broad-complex, tramtrack and bric-a-brac (BTB)-do-
main-containing 33 gene ZBTB33) is a transcriptional fac-
tor that has a BTB/POX domain for the protein-protein
interaction in the amino-terminal portion and a “Zinc
Finger” domain for interaction with DNA in the carboxyl-
terminal portion [18,19]. Due to the aforementioned char-
acteristics Kaiso is member of a subfamily of “zinc finger”
proteins known as POZ-ZF [19].
Most members of this subfamily (POZ-ZF) transcrip-
tional factors including, Kaiso, BCL6, PLZF, HIC-1, FAZF,
APM1, MIZ-1, ZBTB7 and champignon are involved in
the process of cancer development [20-26].
Kaiso protein interacts specifically with p120 catenin
(p120ctn), a member of the armadillo family that owns β-
catenin [19]. β-catenin and p120ctn are very similar mole-
cules possessing the two i. domains of interaction with the
cytosolic portion of cadherins and ii. the ability to translo-
cate from the cytoplasm to the nucleus [27]. A p120ctn is
a regulator of the kaiso function and it is known that in
the nucleus of the cell they directly modulate the action of
canonical Wnt pathways and target genes of β-catenin,
which is another indication of the importance of Kaiso in
the development of cancer [28].
The genes transcriptionally regulated by Kaiso are
matrilysin [14], c-myc and cyclin D1 [17], all of them
widely known for their involvement in cell proliferation
and metastasis and all also regulated by the domain “Zinc
finger” of Kaiso [28]. Gene Wnt11 is another important
and well- known regulatory target, which belongs to the
non-canonical Wnt pathways [29].
The Kaiso protein, unlike other members of the subfam-
ily, appears to be the only factor with bimodal features in
their interaction with DNA, being able to interact specific-
ally with methylated CpG island sites and with consensus
DNA sequences CTGCNA [30,31]. Kaiso apparently
recognize methylated DNA by a canonical mechanism [32]
and their epigenetic function has been widely described as
a transcriptional repressor (revised in [33]). This recogni-
tion of DNA methylation is important for the epigenetic si-
lencing of tumor suppressor genes, which is an essential
role of Kaiso in colon cancer development processes [34].
A breakthrough in understanding how methylation-
mediated repression worked was the finding that Kaiso
interacts with a co-repressor complex containing histone
deacetylase (HDAC). Regarding epigenetic silencing, the
Kaiso protein also acts as a histone-deacetylase-dependent
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deacetylation of histones and these changes facilitate more
closed chromatin conformation and restrict gene transcrip-
tion. The HDAC acts as a protein complex with corepres-
sors recruited. Some of them are directly recruited by
Kaiso as NCOR1 (nuclear receptor co-repressor 1) [35]
and SIN3A [17].
Recently a clinic study has shown for the first time that
the subcellular localization of Kaiso in the cytoplasm of a
cell is directly associated with the poor prognosis of
patients with lung cancer [36]. Such data shows a direct
relationship between the clinical profile of patients with
pathological expression of Kaiso. Therefore, evidence of
changes in subcellular localization seems to be relevant to
the diagnosis and prognosis of lung tumors.
Despite the growing number of experimental data
demonstrating the direct regulatory role of Kaiso on: (i)
canonical Wnt pathways, activation of β-catenin and de-
regulation of the Wnt signaling pathways, it is consid-
ered today as a common phenomenon in cancer and
leukemia [37], (ii) non-canonical Wnt pathways, Wnt11
is directly regulated by β-catenin and Kaiso [15], (iii) the
role of Kaiso in tumorigenesis and (iv) the direct rela-
tionship between cytoplasmic Kaiso and the clinical pro-
file of disease [36], there are no data on the involvement
of Kaiso in hematopoiesis and CML and also there are
no data linking Kaiso with the blast crisis of the disease.
We studied the localization and the role of Kaiso in the
cell differentiation status of the K562 cell line, established
from a CML patient in blast crisis. Using western blot and
immunofluorescence we found for the first time, the cyto-
plasmic distribution of kaiso in CML-BP cells, and consist-
ent with the poor prognosis on the acute phase of the
disease. The imatinib-resistant K562 cells showed a signifi-
cant reduction in the cytoplasmic Kaiso expression. We
next investigated, through siRNA, whether knock-down ei-
ther Kaiso or p120ctn alone or in combination affects the
cell differentiation status of K562 cells. We quantified the
levels of hematopoietic cell differentiation and proliferation
genes: SCF, c/EBPα, c-Myb, GATA-2, PU.1, Wnt11, by
QRT-PCR and (ii) maturation markers of hematopoietic
cells such as CD15, CD11b, CD33 and CD117, by FACS
analysis. We found that knock-down of either Kaiso or
p120ctn alone or combination decreased PU-1, C/EBPα,
Gata-2 and increased SCF and c-MyB levels. Also, the
combined Kaiso and P120ctn knock-down had a 51% in-
duction in cell proliferation compared to the scrambled
knock-down cells. The Kaiso or P120ctn knock-down
alone or double knock-down decreased CD15, CD33 and
CD117 levels when compared to scrambled knock-down
cells. Taken together, these results suggest that Kaiso and
p120ctn contributes to maintaining the undifferentiated
state of the CML-BP and Kaiso seems to be a central mol-




K562 and LAMA-84 cell line were maintained in RPMI
1640 medium supplemented with 10% foetal bovine serum
(Hyclone), 100 U/ml penicillin (Invitrogen), 100 mg/mL
streptomycin (Invitrogen) at 37°C in 5% CO2. K562, estab-
lished from a CML patient in blast crisis [38], was used as
a BCR-ABL-positive cell line. Imatinib-resistant K562 cell
line (a gift from A. Mencalha, INCA RJ) was obtained by
in vitro passaging of K562 in progressively increasing
doses of imatinib. LAMA-84 is a human leucocytic cell
line with basophilic characteristic [39].
Bone marrow samples
All samples were obtained from patients admitted to or
registered at the Instituto Nacional de Câncer (Rio de
Janeiro, Brazil), following the guidelines of the local Eth-
ics Committee and the Helsinki declaration. Diagnoses
and follow-up were based on hematologic, cytogenetic
and molecular assays.
Drug treatment
K562 cell line were exposed to different doses of Imatinib
dissolved in Dimethyl sulphoxide (DMSO; Sigma Aldrich).
DMSO-treated cells were used as vehicle controls.
Viability determination
The viability of cells was measured using a 4-[3-(4-Iodo-
phenyl)-2-(4-nitrophenyl)-2 H-5-tetrazolio]-1,3-benzene
disulphonate (WST-1) assay (Roche). Approximately
2 × 105cells/mL. Cells were plated into 96-well micro-
plates (Corning) for 24 h. After 24 h, 10 μL WST-1 was
added to each well, and plates were incubated at 37°C
for an additional 2 h. Plates were read on a microplate
reader (Bio-Rad, model 550) at 450 nm with a reference
wavelength at 630 nm.
RNAi knockdown and transfection
All RNA oligonucleotides described in this study were
synthesized and purified using highperformance liquid
chromatography (HPLC) at Integrated DNA Technologies
(Coralville, Iowa), and the duplex sequences are available
upon request. RNAi knockdown and transfections were
performed following the manufacturer’s protocols of the
TriFECTa Dicer-Substrate RNAi kit (Integrated DNA
Technologies, Coralville, IA) and the CodeBreaker siRNA
Transfection Reagent (Promega,USA). K562 cells (1× 106
cells per well) were split in 24-well plates to 60% confluency
in RPMI media 1 day prior to transfection. The TriFECTa
kit contains control sequences for RNAi experiments which
include a fluorescent-labeled transfection control duplex
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that is absent in human, mouse, and rat genomes. Fluores-
cence microscopy and FACS monitored the transfection ef-
ficiency according to the manufacturer’s recommendations.
Only experiments in which transfection efficiencies were≥
90% were evaluated. RNA levels were measured 36 h after
transfection, and protein levels were measured 80 h later.
All duplexes used were evaluated at 25, 10, 1, and 0.1 nM.
All transfections were minimally performed in triplicate,
and the data were averaged. Knockdown of Kaiso and
P120ctn was performed, and RNA, protein extraction,
QRT-PCR, Western blot, and FACS analysis were done as
described above.
Real time PCR
QRT-PCR Analysis Quantitation of Kaiso, P120ctn, Wnt11,
β-catenin, SCF, c-MYB, c-EBPα, Gata-2, PU-1 RNA tran-
scripts was carried out by real time PCR (QRT-PCR). Two
micrograms of total RNA from K562 cell line or transfected
K562 cell line, were reverse transcribed with Superscript III
Reverse transcriptaseVR (Invitrogen). cDNAs were mixed
with SYBR Green PCR Master MixVR (Applied Biosys-
tems) and specific primers. Real time PCR was performed
in an ABI Prism 7000 thermocycler (Applied Biosystems),
with 50 cycles of 15 s at 95°C and 2 m at 68°C. Expression
levels were estimated in triplicate with specific and control
primers. For each sample, the relative amounts of tran-
scripts of the target gene and the internal control were esti-
mated from a standard curve. Results were expressed in
arbitrary units as the ratio of the target gene transcript/in-
ternal transcript (data represented by average±SD of three
measurements).
Western blot analysis
Protein lysates were prepared as previously reported [40].
Protein concentrations were determined by the Bradford
method. Approximately 200 μg protein was resolved on 7%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) gels, blotted onto nitrocellulose membranes
(Bio-Rad, CA) and probed with individual antibodies, and
visualized by the enhanced chemiluminescence ECL Plus
Western Blotting Detection ReagentsVR (GE healthy care,
United Kingdom). The following antibodies were used:
anti-kaiso (Santa Cruz Biotechnology, Santa Cruz, CA),
anti-actin (Santa Cruz Biotechnology, Santa Cruz, CA).
The secondary antibodies were horseradish peroxidase
(HRP)-conjugated rabbit antimouse IgG (Santa Cruz Bio-
technology, Santa Cruz, CA).
Immunofluorescence and FACS analysis
K562 cells were incubated in RPMI (Invitrogen, USA),
harvested after 16 h, and washed several times in PBS.
Normal and imatinib-resistant K562 cells were resus-
pended at a concentration of 2 × 106/ml in PBS. Normaland imatinib-resistant K562 cells (50,000) were attached
to microscope slides by centrifugation for 2 min at
800 rpm at high acceleration in a Cytospin 2 centrifuge
(Shandon; Frankfurt, Germany) and dried for 10 min at
37°C in a sterilizer. For immunofluorescence, culture cell
were prefixed in formaldehyde vapor by placing the slide
into a chamber containing paper towel embedded with for-
maldehyde for 10 min. Subsequently, the slides were
immersed in buffered 4% paraformaldehyde for 15 min.
After several washes in phosphate-buffered saline (PBS; pH
7.4), K562 cells were incubated for 72 h at 4°C with primary
antibodies diluted in PBS with 0.3% Triton-X 100 (Reagen,
Curitiba, PR, Brazil) and 5% normal goat serum (Invitro-
gen, Carlsbad, CA). Primary antibodies were the following:
anti-Kaiso (mouse 1:100; Santa Cruz, CA), anti β-tubulin
(mouse 1:500; Sigma), Secondary antibodies were incubated
for 2 h at room temperature. Secondary antibodies were
the following: goat anti-mouse IgG conjugated with Cy3
(1:800; Jackson ImmunoResearch). Slides were counter-
stained with DAPI (Molecular Probes). Conventional fluor-
escence microscopy was performed in an Eclipse TE200
inverted microscope (Nikon, Tokyo, Japan), equipped with
a CoolSNAP-Pro cf CCD camera(Media Cybernetics, Silver
Spring, MD; monochrome). Images were acquired with the
aid of Image-Pro Express software (version 4.5.1.3) and edi-
ted with Photoshop CS5.1 (Adobe, San Jose, CA). For
FACS analysis, antibodies that recognize cell surface
myeloid-specific antigens GPA-phycoerythrin (PE), CD33-
fluorescein isothiocyanate (FITC), CD11b-PE, CD15-FITC,
CD117-PE, CD71-FITC (Becton Dickinson) were used.
Appropriated isotype-matched controls (Becton Dickinson)
were used.
Immunohistochemistry
Immunohistochemical staining was performed in formalin-
fixed, paraffin-embedded bone marrow slides from five
CML patients in the chronic phase and six patients in the
blastic phase, according to standard procedures. Heat-
induced epitopes were retrieved in Tris buffer (pH = 9.9;
Dako, Denmark) in a microwave processor. Tissue sections
were subsequently incubated with anti-KAISO (1:1000)
overnight and with anti-goat immunoglobulin G and per-
oxidase for 30 minutes at room temperature. Slides were
developed using 3,3´-diaminobenzidine/H2O2 (Dako, Den-
mark) and a hematoxylin counterstain. Slides were analyzed
and photographed with a Nikon Eclipse E600 microscope.
Statistical analysis
Data are expressed as means ± standard deviation (SD).
The significance of differences between control and trea-
ted groups was evaluated using one-way analysis of vari-
ance (ANOVA). Experimental tests were performed at
least three times. Differences were considered to be sig-
nificant when P< 0.05.
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1. Kaiso: Cytoplasmic distribution of CML-BP.
The studies in lung cancer have confirmed a cytoplasmic
localization of Kaiso and associated with a poor progno-
sis of the patient [36,41]. To date, there is no evidence
for the involvement of Kaiso in CML-BP. So we started
by characterizing its subcellular distribution in K562 cell
line since it has been considered as a cellular model of
CML-BP. Being a more advanced phase of CML and has
a poor prognosis for the patient, since some of them are
resistant to imatinib therapy [3,7], it seemed appropriate
to begin to characterize these cells.
Immunofluorescence analysis showed the cytoplasmic
distribution/accumulation of Kaiso in K562 cell line
(Figure 1A). A halo of expression can be clearly observed
around the nucleus, involving the whole cytoplasm. For
clarifying whether the subcellular distribution of Kaiso in
K562 cells correlates with BCR/ABL activity, connecting
Kaiso directly to CML, we performed inhibition of BCR/
ABL by imatinib after 16 h of treatment. The immuno-
fluorescence labeling of kaiso showed its presence predom-
inantly in the cytoplasm of K562 cells administered with
imatinib (Figure 1B). In K562 cells treated with imatinib,
β-tubulin was also mainly in the cytoplasm (data not
shown). Kaiso labeling was not found in the K562 cells
incubated with non-immune serum (data not shown).
To confirm the cytoplasmic localization of Kaiso in
CML-BP, we analyzed cytoplasmic expression of Kaiso
protein by western blot analysis, comparing expression in
cytoplasmic and nuclear protein extracts in K562 cell line
(Figure 1D) and imatinib-resistant K562 cell line (Figure 1D).
Significant cytoplasmic expression of Kaiso was only
observed in K562 cell line whereas in imatinib-resistant
K562 cell line was clearly down-regulated (Figure 1D). We
also confirmed the weak expression of Kaiso in imatinib-
resistant K562 cell line by immunofluorescence (Figure 1B).
Also by western blot, we confirmed that treatment with ima-
tinib (0.1 and 1 uM) and siRNAp120ctn, did not disturb the
expression of Kaiso (Figure 1C).
2. RNAi knock-down of kaiso in K562 cells improves
survival and proliferation.
Given that Kaiso is overexpressed in the cytoplasm of
K562 cells, this study set out to examine how loss of Kaiso
and their partner p120ctn affected gene expression and
cell proliferation of CML-BP. To inactivate Kaiso and
p120ctn we employed siRNA targeting each gene as
described in the materials and methods. We developed a
transfection protocol that led to over 96% of the K562 cells
taking up the siRNA (data not shown). Next, the effective-
ness of the knockdown was assessed using QRT-PCR
(Figure 2C) and Western blotting (Figure 2B). QRT-PCR
analysis showed that Kaiso mRNA levels were decreased
by 80% (Figure 2C) and Western blot analysis showed thatKaiso protein levels were undetectable in K562 cells trans-
fected by siRNA-Kaiso (25 nM for 24 h), when compared
to scrambled knock-down cells (Figure 2B). This result
was confirmed by immunofluorescence in K562 cells
transfected by siRNA-Kaiso, showing the undetectable ex-
pression of Kaiso (Figure 2A). Using siRNA-p120ctn
(10 nM for 24 h) a reduction of 70% in p120ctn was
achieved when compared to scrambled knockdown cells
by QRT-PCR analysis (Figure 2D).
To confirm these results, we analyzed the expression of
two known Kaiso target genes, Wnt11 and β-catenin, using
QRT-PCR. Wnt11 and canonical Wnt/β-catenin signaling
pathway are modulated by Kaiso. K562 cells were either
transfected with siRNA-scrambled that does not target any
human gene or transfected with siRNA to Kaiso or p120ctn
either alone or in combination. Knockdown of Kaiso led to
significant increases by 13% in β-catenin gene expression
(Figure 3A). However, the p120ctn knock-down alone
showed a decrease by 65% in β-catenin levels (Figure 3B)
while the Kaiso/p120ctn double knock-down line did not
substantially affect β-catenin levels in vitro when compared
to scrambled knock-down cells (Figure 3C). Knock-down
either Kaiso or p120ctn alone or in combination led to sig-
nificant reduction of Wnt11 when compared to scrambled
knock-down cells (Figure 3). As is well known that Kaiso
interacts with TCF/LEF1 [15,17], and that the Wnt11 pro-
moter, has regulatory sites for binding TCF protein [42],
these results suggest the inhibitory role of TCF/LEF1-β-
catenin on the expression of Wnt11. In K562 cells trans-
fected by siRNA-p120ctn, Kaiso may be responsible for
Wnt11 repression (Figure 3C).
Since Kaiso is considered a methylation-dependent “op-
portunistic” oncogene, it was conceivable to explore the
biological role of Kaiso on the cells growth in vitro, the pro-
liferation of K562 cells was evaluated by a WST-1 assay. To
knock-down either Kaiso or p120ctn alone or in combin-
ation, we employed siRNA. While the Kaiso knock-down
alone did not show a substantial increase proliferation, the
double knock-down showed a significant increase by 51%
in proliferation, when compared to scrambled knock-down
cells (Figure 4). However, knock-down of p120ctn alone
does not affect proliferation, when compared to scrambled
knock-down cells (Figure 4). Consistent with this finding,
knock-down of either Kaiso or p120ctn alone or in combin-
ation, in K562 cells, led to a significant 10–100 fold in-
crease in SCF expression assessed by QRT-PCR (Figure 5).
This significant increase in SCF expression correlated with
an increase on in vitro cell proliferation.
3. RNAi knock-down of kaiso in K562 cells block
hematopoietic differentiation.
It was previously shown that Wnt11 can modulate
hematopoietic stem cell diversification [43]. As mentioned
above, knock-down of either Kaiso or p120ctn alone or in
combination led to a significant reduction by 80% in
Figure 1 Kaiso subcellular localization in K562 cell line (A). Immunofluorescence staining of Kaiso. Kaiso was distributed in the cytoplasm,
with less visible staining in the nucleus (B). Immunofluorescence of Kaiso in imatinib-resistant K562 cells and K562 cells treated with imatinib. (C).
Expression analysis of Kaiso by immunoblotting assay. Normal bands can be detected after transfection with siRNA-p120ctn and treatment with
imatinib. Little bands can be detected after transfection with siRNA-Kaiso and imatinib-resistant K562 cells. β-tubulin served as an internal control.
(D). To verify effective separation of the cytoplasmic and nuclear fractions, cytoplasmic and nuclear extracts were immunoblotted for Kaiso in
normal (K562) and imatinib-resistant K562 (IR-K562) cell line.
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of Kaiso and p120ctn, by siRNA, affected the cell differenti-
ation status of CML-BP. We quantified the levels of
hematopoietic differentiation genes: C/EBPα, c-Myb,
GATA-2, PU.1, by QRT-PCR analysis. The knock-down of
Kaiso alone or Kaiso/p120ctn double knock-down,
increased c-MyB by 65% and decreased PU-1, C/EBPα and
Gata-2 by 66%, 80% and 50% respectively, when compared
to scrambled knock-down cells (Figure 6A and C). The
knock-down of p120ctn alone decreased PU1 and Gata-2
by 57% and 51% respectively when compared to scrambled
knock-down cells (Figure 6B). This leads us to think that
the effect of knock-down Kaiso and p120ctn would block
cell differentiation and increase proliferation of cells simul-
taneously in CML-BP.
We next investigated whether knock-down either Kaiso
or p120ctn alone or in combination affects the global cell
differentiation, now evaluating the maturation markers of
hematopoietic differentiation CD15, CD11b, CD33 and
CD117 expressed in the plasma membrane of K562 cells
by FACS analysis. CD15 and CD11b were used widely as
indicators of maturation of the hematopoietic cells and also
as granulocytic markers [40]. We found that knock-down
of Kaiso or p120 alone or Kaiso/p120ctn double knock-
down decreased CD15, CD33 and CD117 by 25-35%, 8%and 13% respectively (Figure 7). These finding indicate that
knock-down of Kaiso and p120ctn are blocking the differ-
entiation program of CML-BP. Finally, the down regulation
of Kaiso and p120ctn decreased CD117 by 13% which is
quite expected from the large amount of SCF expression
(Figure 5), suggesting down regulation of cell surface
CD117/KIT receptors by an autocrine signaling mechanism.
In order to confirm the molecular analysis in K562 we
used another CML-BP cell line, LAMA-84 (Figure 8).
The main difference between the cell lines K562 and
LAMA-84 is the expression of β-catenin in response to the
Kaiso knock-down. The knock-down of Kaiso increased
β-catenin by 13% in K562 cell line (Figure 3A) and
decreased by 62% in LAMA-84 cell line (Figure 8A) when
compared to scrambled knock-down cells. This different
behavior can be explained because LAMA-84 and K562 are
cells in blast crisis, but with different origins. LAMA-84 is
a human leucocytic cell line with basophilic characteristic
[39] and K562 is a erythroblastic cell line with granulocytic
and erythroid characteristics [38], besides being very much
more differentiated than LAMA-84.
Finally to confirm the cytoplasmic localization of Kaiso,
by immunohistochemistry, we compared their expression
in CML bone marrow from patients in chronic and in
Figure 2 siRNA-Kaiso efficiently down-regulates cytoplasmic Kaiso expression in K562 cell line. (A). Immunofluorescence staining of Kaiso
and β-tubulin. siRNA-Kaiso only efficiently downregulated cytoplasmic Kaiso expression in k562 cell line when compared to the scrambled knock-
down cells (B). Cytoplasmic vs. nuclear fractionation Western blot analysis confirmed the results of immunofluorescence staining. β-tubulin served
as an internal control. (C). Expression analysis of Kaiso knock-down by Real Time RT-PCR. (D). Expression analysis of p120ctn knock-down by Real
Time RT-PCR. Data were expressed as mean± standard deviation (S.D.). Columns, mean (n = 3); error bars, S.D.
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two compared phases (Figure 9) and it can be argued that
their cytoplasmic expression is significantly higher in blastic
phase.Discussion
Kaiso and cancer
The Kaiso protein, like other members of the subfamily
POZ-ZF [20,22,25,44-48], has been implicated in cancer de-
velopment process when it has been found that Kaiso inhi-
bits activation mediated by β-catenin of the Mmp7 gene
(also known as matrilysin), which is well known for meta-
static spread [14]. Recently another study suggests that
Kaiso can regulate TCF/LEF1-activity, via modulating
HDAC1 and β-catenin-complex formation [15]. This shows
that Kaiso can directly regulate the signaling pathway of ca-
nonical Wnt/β-catenin widely known for its involvement in
human tumors. The Kaiso overexpression decreases theability of TCF/LEF to interact with β-catenin, which implies
that Kaiso and TCF/LEF are associated in the nucleus [17].Kaiso and prognosis
As expected for a transcriptional factor, the Kaiso protein
is often found in the nucleus of several tumor or non-
tumor derived mammalian cell lines [28]. Recent studies
using immunohistochemistry analysis of normal and
tumor tissue revealed that Kaiso protein is predominantly
localized in the cytoplasm of the cell or is totally absent,
though [49]. These data are consistent with the results
found in the K562 cell line in which expression of the
Kaiso is predominantly cytoplasmic (Figures 1 and 2). This
seems to be unusual because Kaiso has a signal “NLS”
highly conserved and required for any protein with nu-
clear localization. Moreover, Kaiso uses classical nuclear
transport mechanisms through interaction with Importin
α/β nuclear [50]. One possible explanation is that Kaiso,
Figure 3 Expression analysis of Wnt11, β-catenin, Kaiso and p120ctn genes in either Kaiso (A) or p120ctn (B) alone or in combination
(C) knock-down cells. K562 cells were transfected with the indicated siRNA combinations. Twenty-four hours later, RNA was isolated and
subjected to Real Time RT-PCR to quantify expression of Wnt11, β-catenin, Kaiso and p120ctn after normalization to β-actin and compared to the
scrambled knock-down cells. Data were expressed as mean± standard deviation (S.D.). Columns, mean (n = 3); error bars, S.D.; *, p< 0.001.
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http://www.cancerci.com/content/12/1/28like other proteins or factors that normally reside in the
cytoplasm, require a post-translational modification, to be
targeted and translocated to the cell nucleus.
However, 2009 data has shown for the first time that the
subcellular localization of Kaiso in the cytoplasm of a cell
is directly associated with the poor prognosis of patients
with lung cancer (non-small cell), and around 85 to 95%
of lung cancers are non-small cell [36]. Such data shows aFigure 4 Down-regulated cytoplasmic Kaiso and p120ctn
enhance the proliferative ability of K562 cells. Cell proliferation
was determined using the WST-1 assay. The growth rate was
significantly higher in siRNAKaiso/p120ctn double knock-down,
when compared to scrambled knock-down cells. Data were
expressed as mean± standard deviation (S.D.). Columns, mean
(n = 3); error bars, S.D.; *, p< 0.001.direct relationship between the clinical profile of patients
with pathological expression of Kaiso.
Surprisingly in this paper we describe for the first time a
relationship between the cytoplasmic Kaiso to CML-BP.
An interesting aspect of our results is the relationship be-
tween cytoplasmic Kaiso to the prognosis expected in blast
crisis (Figure 2). At this stage of the disease, many patients
died between three and six months, because they areFigure 5 Expression analysis of SCF gene by Real Time RT-PCR
in either Kaiso or p120ctn alone or in combination knock-down
cells. Data were expressed as mean± standard deviation (S.D.).
Columns, mean (n = 3); error bars, S.D.; *, p< 0.001.
Figure 6 Kaiso knock-down inhibits cell differentiation. K562 cells were transfected with the indicated siRNA combinations. Twenty-four
hours later, RNA was isolated and subjected to Real Time RT-PCR to quantify expression of C-MyB, PU-1, C/EBPalpha and Gata-2 after
normalization to β-actin and compared to the scrambled knock-down cells. Data were expressed as mean ± standard deviation (S.D.). Columns,
mean (n = 3); error bars, S.D.; *, p< 0.001.
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http://www.cancerci.com/content/12/1/28refractory to most treatments. In CML progression to
accelerated phase and blastic phase appears to be due
mainly to genomic instability, which predisposes to the de-
velopment of other molecular abnormalities. The mechan-
isms of disease progression and cytogenetic evolution to
blast crisis remain unknown.
Canonical and non-canonical Wnt pathways regulation of
Wnt 11
The Wnt11 promoter contains two conserved TCF/LEF
binding sites (at −43 for each of the alternative first exons)
and one Kaiso binding site (at −775 in the human gene),
suggesting that both canonical [42] and non canonical Wnt
pathways can down regulate Wnt11 transcription directly.
Consistent with this, Kaiso depletion strongly increase
Wnt11 expression in Xenopus [29]. On the contrary, in
K562 cells, upon Kaiso knock-down we observed a signifi-
cant decrease in the Wnt11 expression (Figure 3A–C). A
possible explanation of this controversy is that knock-down
of Kaiso, increased β-catenin expression (Figure 3A), and
this is a likely reason for the maintenance of Wnt11 repres-
sion in the absence of Kaiso. As is well known, Wnt11 isactually one of several β-catenin/TCF target genes that con-
tain adjacent putative Kaiso and TCF/LEF binding sites in
their promoter, suggesting that Kaiso and TCF/LEF cooper-
ate to repress Wnt11transcription [16].
Our results therefore indicate the cooperation between
β-catenin/TCF and Kaiso/p120ctn in negative regulation
of Wnt11. A common theme among all these studies is
that while Wnt11 expression can be regulated by canon-
ical Wnt signals, this regulation is highly dependent on
transcription factors in addition to, or other than, TCF/
LEF family members, for example, Kaiso/p120ctn.
Kaiso and resistance to imatinib therapy
The novel anticancer agent, imatinib (Glivec, Gleevec,
formerly STI571, CGP57148) has proven to be a highly
promising treatment for CML. The drug selectively inhibits
the kinase activity of the BCR/ABL fusion protein [4,5].
Although the majority of CML patients treated with
imatinib show significant hematologic and cytogenetic
responses, resistance to imatinib is clearly a barrier to
successful treatment of CML patients. In some patients,
resistance arises due to powerful selective pressure on
Figure 7 Knocking-down expression of Kaiso in K562 cells reduced monocyte-macrophage differentiation. Flow cytometric measurement
of granulocytic specific surface antigen CD15 and CD11b in K562 cells after normalization with the scrambled knock-down expression. K562 cells
were transfected with the indicated siRNA combinations A, B and C. The CD117 (c-Kit receptor), CD33 and the erythroid markers GPA and CD71
were also analyzed. (D) CD15 expression in K562 knockdown cells. M1 represents unlabeled K562 scrambled control. M2 represents K562
scrambled control labeled with CD15 and M3 represents K562 cells transfected with Kaiso duplex (10 nM) after 50 h-incubation. Data were
expressed as mean± standard deviation (S.D.). Columns, mean (n = 3); error bars, S.D.; *, p< 0.001.
when either Kaiso or p120ctn alone or in combination
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http://www.cancerci.com/content/12/1/28rare cells that carry amplified copies of the BCR-ABL
fusion oncogene or point mutations in the BCR-ABL
tyrosine kinase domain that affect binding of the drug to
the oncoprotein. However, in a proportion of patients
neither mechanism operates, and resistance appears to
be a priori, existing prior to exposure to the drug [51].
These mechanisms of imatinib resistance are poorly
understood and heterogeneous involving largely BCR-
ABL independent mechanisms [51,52].
Our results show that imatinib-resistant K562 cells has a
weak expression of Kaiso in the cytoplasm and with a simi-
lar phenotype, but not identical, to Kaiso knock-down cells
(Figure 1B–D). This result suggests the down regulation of
Kaiso as a mechanism of resistance to imatinib. Obviously
cannot rule out that weak expression in the imatinib-
resistant K562 cell line, is a secondary effect involving
other genes that lead to transcriptional and translational
repression of Kaiso. So far, no proteomics studies, using
high-throughput technologies, identified Kaiso as a gene
potentially involved in the acquisition of resistance to ima-
tinib [53,54].
Extensive changes in gene expression underlie the
biological effects of Kaiso knock-down
The result shows a global change affecting the ex-
pression of several genes important in hematopoieticdifferentiation and proliferation, coherently with the
genome-wide transcriptional response to Kaiso, character-
ized during early vertebrate development [55]. Thus, all
the changes produced by siRNA indicate a trend towards
improvement of cell proliferation and blocks of granulo-
cytic differentiation.
Kaiso knock-down improves cell proliferation
The knock-down of either Kaiso or p120ctn alone or in
combination decreased C/EBPα and PU-1 (Figure 6A
and C) and increased significantly SCF expression
(Figure 5). The transcription factor CCAAT/enhancer
binding protein α (C/EBPα) is a strong inhibitor of cell
proliferation [56]. Accordingly we found that in all
transfections, C/EBPα levels were reduced by 56-80%,
when compared with scrambled knock-down cells.
On the other hand, the transcription factor PU.1 is a
hematopoietic lineage- specific ETS (Erythroblast Trans-
formation Specific) family member [57] that is absolutely
required for normal hematopoiesis [58]. The level of
PU.1 expression is critical for specifying cell fate, and, if
perturbed, even modest decreases in PU.1 can lead to
leukemias and lymphomas [57,59-64]. Coherently, our
results showed that the PU-1 levels decreased by 57-66%levels were decreased by siRNA (Figure 6).
Figure 8 Effect of RNAi knock-down of Kaiso on LAMA-84. (A) Kaiso knock-down induce Wnt11 expression. LAMA-84 cells were transfected
with 20nM of siRNA. Twenty-four hours later, RNA was isolated and subjected to Real Time RT-PCR to quantify expression of Wnt11, β-catenin,
Kaiso and p120ctn after normalization to β-actin and compared to the scrambled knock-down cells. Columns, mean (n= 2). (B) Kaiso knock-down
improve SCF expression in LAMA-84. Expression analysis of SCF gene by Real Time RT-PCR in Kaiso knock-down cells. Columns, mean (n= 2). (C)
Effect of Kaiso knock-down on cell differentiation. LAMA-84 cells were transfected with 20nM of siRNA. Twenty-four hours later, RNA was isolated
and subjected to Real Time RT-PCR to quantify expression of C-MyB, PU-1, C/EBPalpha and Gata-2 after normalization to β-actin and compared to
the scrambled knock-down cells. Columns, mean (n= 2). (D) Knocking-down expression of Kaiso in LAMA-84 cells induced monocyte-
macrophage differentiation. Flow cytometric measurement of granulocytic specific surface antigen CD15 and CD11b in LAMA-84 cells after
normalization with the scrambled knock-down expression. LAMA cells were transfected with 20nM of siRNA after 50 hr-incubation. The CD117
(c-Kit receptor), CD33 and the erythroid markers GPA and CD71 were also analyzed. Columns, mean (n= 2).
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http://www.cancerci.com/content/12/1/28An important aspect of our analysis is that recent data
show a system of autocrine and paracrine activation of c-
kit (CD117) by SCF [65]. These mechanisms stimulate the
growth of Merkel cell carcinoma in vitro. Analysis of the
expression of c-kit on the surface of K562 cells showed a
small but significant reduction of the CD117 receptorFigure 9 Immunohistochemistry staining of Kaiso (A) and (B) in CML
Magnification x 400 fold.expression in cells with knock-down of either Kaiso or
p120ctn alone or in combination (Figure 7). On the other
hand, Kaiso/p120ctn double knock-down led to a signifi-
cant 100 fold increase in SCF expression, important for cell
survival and proliferation (Figure 5). These results could
represent an indirect evidence of autocrine and paracrinebone marrow slides, from blastic and chronic phase patients.
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http://www.cancerci.com/content/12/1/28stimulation of c-kit in K562 cells and justify the effect on
cell proliferation produced by Kaiso/p120ctn double
knock-down.Kaiso knock-down inhibits cell differentiation
Recent studies demonstrate that Kaiso and N-CoR (inter-
acts directly with Kaiso in the nucleus) have important
roles in neural cell differentiation [35,66,67]. Also, the
POZ-ZF subfamily member BCL6 represses several genes
that are necessary for the terminal differentiation of B-
lymphocytes [68]. But there is no evidence to support the
participation of Kaiso in the hematopoietic differentiation.
Our results showed that knock-down of Kaiso decreased
CD15 by 35%, indicating that, reduced expression of
Kaiso, can block differentiation of the granulocytic pro-
gram (Figure 7D). We also analyzed the levels of Wnt11,
C/EBPα and c-MyB and the results in Figure 6 show that
the expression of Wnt11 and C/EBPα were also reduced
and the expression of c-MyB was increased, which is con-
sistent with the Kaiso contribution to the hematopoietic
differentiation.
A major role for Wnt11 in vivo is its ability to promote
differentiation, for example, stimulating cardiac differenti-
ation of mouse embryonic carcinoma P19 cells [69], and
promoting differentiation of many different types of cells
[70-72]. Moreover, Wnt11 promote the differentiation of
QCE6 cells into red blood cells and monocytes at the
expense of macrophages [43], suggesting that Wnt11 can
modulate hematopoietic stem cell diversification. Thus,
the knock-down of Kaiso decreased Wnt11 levels by 78%
(Figure 3), consistent with the role of Kaiso in the
hematopoietic differentiation program.
On the other hand, knock-down of Kaiso reduced C/
EBPα that is a critical regulator of hematopoietic stem cell
homeostasis and myeloid differentiation [73,74]. The
events leading to the loss of C/EBPα function facilitate
leukemogenesis by blocking granulocytic differentiation
[75,76] and coherently the knock-down of Kaiso decreased
CD15 used widely as granulocytic marker (Figure 7A–D).
Interestingly, in vitro experiments have shown that con-
stitutive overexpression of c-Myb blocks differentiation of
myeloid and erythroid cells and the associated growth arrest
that occurs with maturation. However, c-myb-antisense
-treated HL-60 cells differentiated only into monocytes but
not into granulocytes indicating that granulocytic differenti-
ation, unlike monocytic differentiation, requires c-myb-
mediated proliferation. Consistent with this, an increase ex-
pression of c-MyB resulted in a significant decrease in ex-
pression of CD15 in K562 cells transfected with siRNA-
Kaiso (Compare Figures 6A and 7A). Finally, the myeloid
commitment of hematopoietic progenitors is characterized
by the progressive loss of CD34 expression accompanied by
the acquisition of CD33 expression at high levels. Theknock-down of Kaiso led to a significant decreased by 8%
in CD33 expression (Figure 7).
These findings provide a comprehensive picture of the
changes in proliferation, differentiation, and global gene
expression that underlie of the pivotal role of cytoplas-
mic Kaiso in the blast crisis.Conclusions
Our results are promising first because they allow the es-
tablishment of relationship between blast crisis to cellular
distribution of Kaiso, and second, by the extensive changes
in gene expression underlie the biological effects of Kaiso
knock-down and third because the epigenetic regulation of
Kaiso make CML a particularly attractive disease for epi-
genetic drug targets.
Although the epigenome offers promising targets for
novel anticancer therapy, an important obstacle still need
to be considered. Where is Kaiso in the cytoplasm? What
is the role of endocytic membrane in the disease progres-
sion? It is now widely accepted that systems of endocytic
membrane trafficking and intracellular signaling are closely
interconnected and endosomes could act as signaling plat-
forms [77,78].
Therefore, a view focused on subcellular compartments
and proteins modulating the epigenoma, can provide a
greater understanding of the biology of malignant cells, as
well as improve our approach to cancer treatment [78]. It
is known that cancer treatment is dictated by the stage of
the disease, and that cancer treatment is more effective
during the chronic phase of the disease. Unfortunately,
clinical and molecular tests cannot predict disease pro-
gression, which can create an obstacle to diagnosis: the in-
ability to identify subtypes of patients most likely to
benefit from specific treatment options for specific stages
of the disease, which would make it possible to offer a
therapy targeted to a given cancer patient. The results pre-
sented in this work reveal Kaiso and their subcelular distri-
bution as a potential target for selective therapy of CML.
The understanding of this new biology of CML progres-
sion can provide markers for clinical diagnosis and differ-
ent approximations for better therapeutic strategies.
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